PDF(Pubmed)
Abstract：
UNASSIGNED: Previous studies support the effectiveness of sesame oral immunotherapy (S-OIT) in patients >4 years old using maintenance doses of 1200 mg protein. However, tahini is often not palatable to children, and high-maintenance doses may not be possible for preschoolers.
UNASSIGNED: We studied the safety and effectiveness outcomes of preschoolers with sesame allergy who underwent low-dose S-OIT of 200 mg protein.
UNASSIGNED: Preschoolers with sesame allergy, with a history of objective reaction to sesame, and with either a positive skin prick test result (wheal diameter ≥3 mm) or sesame-specific IgE level ≥0.35 kU/L were included. Doses were escalated every 2 to 4 weeks until the maintenance dose of 200 mg of sesame protein was reached. The maintenance dose was continued daily for 1 year, followed by exit oral food challenge (OFC). Primary safety outcomes included allergic reactions grade 2 or higher and the need for epinephrine therapy during buildup. The primary effectiveness outcome was proportion of patients tolerating a minimum of 2000 mg sesame protein at exit OFC.
UNASSIGNED: Twenty-eight preschoolers (median age, 33.5 months) were enrolled to receive S-OIT. During the buildup phase, 9 subjects (32.1%) had no reaction, and 8 (28.6%) and 11 (39.3%) had grade 1 and 2 reactions, respectively. One patient (3.57%) received epinephrine for a grade 2 reaction. Twenty-one (91.3%) of 23 eligible subjects underwent exit OFC; 18 (85.7%) of these 21 patients successfully completed exit OFC. One (4.8%) and 2 (9.5%) subjects had grade 1 and 2 reactions, respectively, during OFC.
UNASSIGNED: A lower and age-appropriate maintenance dose is safe and effective in desensitizing preschoolers with sesame allergy.
UNASSIGNED: We studied the safety and effectiveness outcomes of preschoolers with sesame allergy who underwent low-dose S-OIT of 200 mg protein.
UNASSIGNED: Preschoolers with sesame allergy, with a history of objective reaction to sesame, and with either a positive skin prick test result (wheal diameter ≥3 mm) or sesame-specific IgE level ≥0.35 kU/L were included. Doses were escalated every 2 to 4 weeks until the maintenance dose of 200 mg of sesame protein was reached. The maintenance dose was continued daily for 1 year, followed by exit oral food challenge (OFC). Primary safety outcomes included allergic reactions grade 2 or higher and the need for epinephrine therapy during buildup. The primary effectiveness outcome was proportion of patients tolerating a minimum of 2000 mg sesame protein at exit OFC.
UNASSIGNED: Twenty-eight preschoolers (median age, 33.5 months) were enrolled to receive S-OIT. During the buildup phase, 9 subjects (32.1%) had no reaction, and 8 (28.6%) and 11 (39.3%) had grade 1 and 2 reactions, respectively. One patient (3.57%) received epinephrine for a grade 2 reaction. Twenty-one (91.3%) of 23 eligible subjects underwent exit OFC; 18 (85.7%) of these 21 patients successfully completed exit OFC. One (4.8%) and 2 (9.5%) subjects had grade 1 and 2 reactions, respectively, during OFC.
UNASSIGNED: A lower and age-appropriate maintenance dose is safe and effective in desensitizing preschoolers with sesame allergy.
摘要：
■先前的研究支持芝麻口服免疫疗法（S-OIT）在4岁以上患者中使用1200mg蛋白质的维持剂量的有效性。然而,芝麻酱通常不适合儿童，和高维持剂量可能是不可能的学龄前儿童。
■我们研究了患有芝麻过敏的学龄前儿童接受200mg蛋白质低剂量S-OIT的安全性和有效性结果。
■芝麻过敏的学龄前儿童，对芝麻有客观反应的历史，包括皮肤点刺试验结果阳性（风团直径≥3mm）或芝麻特异性IgE水平≥0.35kU/L。每2至4周增加剂量,直到达到200mg芝麻蛋白的维持剂量。维持剂量每天持续1年，其次是退出口腔食物挑战（OFC）。主要安全性结果包括2级或更高的过敏反应以及在累积期间需要肾上腺素治疗。主要有效性结果是在退出OFC时耐受至少2000mg芝麻蛋白的患者比例。
■28名学龄前儿童（中位年龄，33.5个月)登记接受S-OIT。在积累阶段，9名受试者（32.1%）无反应，8例（28.6%）和11例（39.3%）有1级和2级反应，分别。一名患者（3.57％）接受肾上腺素治疗2级反应。23名符合条件的受试者中有21名（91.3％）接受了退出OFC；这21名患者中有18名（85.7％）成功完成了退出OFC。1名（4.8%）和2名（9.5%）受试者有1级和2级反应，分别,在OFC期间。
■较低和适合年龄的维持剂量对芝麻过敏的学龄前儿童脱敏是安全有效的。
■我们研究了患有芝麻过敏的学龄前儿童接受200mg蛋白质低剂量S-OIT的安全性和有效性结果。
■芝麻过敏的学龄前儿童，对芝麻有客观反应的历史，包括皮肤点刺试验结果阳性（风团直径≥3mm）或芝麻特异性IgE水平≥0.35kU/L。每2至4周增加剂量,直到达到200mg芝麻蛋白的维持剂量。维持剂量每天持续1年，其次是退出口腔食物挑战（OFC）。主要安全性结果包括2级或更高的过敏反应以及在累积期间需要肾上腺素治疗。主要有效性结果是在退出OFC时耐受至少2000mg芝麻蛋白的患者比例。
■28名学龄前儿童（中位年龄，33.5个月)登记接受S-OIT。在积累阶段，9名受试者（32.1%）无反应，8例（28.6%）和11例（39.3%）有1级和2级反应，分别。一名患者（3.57％）接受肾上腺素治疗2级反应。23名符合条件的受试者中有21名（91.3％）接受了退出OFC；这21名患者中有18名（85.7％）成功完成了退出OFC。1名（4.8%）和2名（9.5%）受试者有1级和2级反应，分别,在OFC期间。
■较低和适合年龄的维持剂量对芝麻过敏的学龄前儿童脱敏是安全有效的。
